Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 6/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.39 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MASP2 | O00187 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | XBP1 | P17861 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | CCR6 | P51684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2891199 | 0.81 | ATM (0.49) | LMNAESR1ESR2SCN2ARECQL | |
| SCHEMBL5846779 | 0.77 | LMNA (0.61) | LMNAESR1ESR2SCN2ARECQL | |
| SCHEMBL1635525 | 0.75 | SCN2A (0.54) | LMNASCN2ACA2CA9MEN1 | |
| SCHEMBL2891317 | 0.74 | LPAR3 (0.48) | LMNAESR1ESR2SCN2ARECQL | |
| SCHEMBL11305617 | 0.72 | ESR1 (0.57) | LMNAESR1ESR2SCN2ARECQL | |
| SCHEMBL11000006 | 0.72 | ESR1 (0.47) | LMNAESR1ESR2SCN2ARECQL | |
| SCHEMBL4198055 | 0.72 | LMNA (0.56) | LMNAESR1ESR2SCN2ARECQL | |
| SCHEMBL16655162 | 0.70 | ESR1 (0.57) | LMNAESR1ESR2SCN2ARECQL | |
| SCHEMBL11863055 | 0.70 | ESR1 (0.57) | LMNAESR1ESR2SCN2AMEN1 | |
| SCHEMBL5579665 | 0.70 | ESR1 (0.83) | LMNAESR1ESR2SCN2ARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112097-A1 | Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-05-12 | — | — | US | disclosed |
| US-7932416-B2 | Prepared by electrophilic aromatic substitution via halogenation, chlorosulfonation or nitration of a pentafluorosulfanylbenzene; 2-Methyl-5-nitro-4-pentafluorosulfuranylbenzoic acid; for liquid crystals, polymers, pesticides, herbicides, fungicides, nematocides, parasiticides, insecticides, acaricides | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-04-26 | — | — | US | disclosed |
| US-7932416-B2 | Prepared by electrophilic aromatic substitution via halogenation, chlorosulfonation or nitration of a pentafluorosulfanylbenzene; 2-Methyl-5-nitro-4-pentafluorosulfuranylbenzoic acid; for liquid crystals, polymers, pesticides, herbicides, fungicides, nematocides, parasiticides, insecticides, acaricides | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-04-26 | — | — | US | disclosed |
| US-7759366-B2 | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use | SANOFI-AVENTIS (FR) | 2010-07-20 | — | — | US | disclosed |
| US-20090215728-A1 | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use | SANOFI-AVENTIS (FR) | 2009-08-27 | — | — | US | disclosed |
| US-20080091031-A1 | Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates | SANOFI-AVENTIS DEUTSCHLAND GMBH (FR) | 2008-04-17 | — | — | US | disclosed |
| US-20080091031-A1 | Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates | SANOFI-AVENTIS DEUTSCHLAND GMBH (FR) | 2008-04-17 | — | — | US | disclosed |
| US-7317124-B2 | Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-01-08 | — | — | US | disclosed |
| US-7317124-B2 | Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-01-08 | — | — | US | disclosed |
| US-20050148652-A1 | Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148652-A1 | Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates | PFAS, DDT, PNPO | LMNA 4572/4885ESR1 3689/4885ESR2 4768/4885 |
| US-20090215728-A1 | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use | GPR119, GIPR, LIPC | LMNA 815/4885ESR1 2311/4885ESR2 1523/4885 |
| US-20080091031-A1 | Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates | PFAS, DDT, PNPO | LMNA 4572/4885ESR1 3689/4885ESR2 4768/4885 |
| US-20110112097-A1 | Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | GIPR, PGC, DDC | LMNA 1453/4885ESR1 1988/4885ESR2 1787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.